Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia(®)) in Brazil; Implications for Future Pricing Considerations

Introduction and Objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Godói, Isabella P., Santos, André S., Reis, Edna A., Lemos, Livia L. P., Brandão, Cristina M. R., Alvares, Juliana, Acurcio, Francisco A., Godman, Brian, Guerra Júnior, Augusto A.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2017
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5288336/
https://ncbi.nlm.nih.gov/pubmed/28210223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00041
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados